Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evaxion Biotech ( (EVAX) ) has issued an update.
On January 13, 2026, Evaxion A/S announced that it is expanding its AI-Immunology platform into autoimmune diseases, adding this as a third core therapeutic area alongside cancer and infectious diseases. The move is intended to leverage the scalability of its AI technology to generate a broader and higher-quality pipeline of precision treatments that address underlying disease mechanisms rather than just symptoms, thereby enhancing the company’s partnership potential across all stages of drug development. Evaxion stated that the training of AI-Immunology for autoimmune applications is planned for the second half of 2026 and that this work is already incorporated into its financial plans, with its cash runway still expected to extend into the second half of 2027. The company also outlined key 2026 milestones, including additional biomarker and immunogenicity data and three-year Phase 2 efficacy data for EVX-01, a regulatory filing for a Phase 1 trial of EVX-04, a preclinical antigen design milestone for EVX-B4, and the launch of the new autoimmune application, underscoring continued execution of its strategy to create value from both its platform and pipeline assets through partnerships.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong technical indicators and positive earnings call highlights, including a significant deal with MSD and promising clinical data. However, financial challenges such as persistent net losses and reliance on debt weigh down the score. The valuation remains unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based, clinical-stage TechBio company that uses its proprietary AI-Immunology platform to decode the human immune system and develop AI-powered vaccines and novel immunotherapies. The company focuses on oncology and infectious diseases, with a clinical-stage pipeline of personalized cancer vaccines and a preclinical portfolio targeting bacterial and viral infections with high unmet medical need.
Average Trading Volume: 241,463
Technical Sentiment Signal: Sell
Current Market Cap: $32.09M
Learn more about EVAX stock on TipRanks’ Stock Analysis page.